These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 10622046)

  • 1. Interactive debate.
    Gazzard B
    Int J Clin Pract Suppl; 1999 Jun; 103():49-52. PubMed ID: 10622046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Options for first line therapy.
    Proj Inf Perspect; 1999 Apr; (27):7-8. PubMed ID: 11366741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third line anti-HIV therapy options.
    Proj Inf Perspect; 2004 Jan; (37):19-21. PubMed ID: 15119286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Salvage therapy in HIV infection].
    Salzberger B
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():52, 54-5, 57. PubMed ID: 15373050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. After the drugs: what's next?
    Schouten JT
    Res Initiat Treat Action; 1998 Dec; 4(7):9-10. PubMed ID: 11366085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antiretroviral therapy guidelines.
    Vella S
    AIDS Clin Care; 1996 Oct; 8(10):79-81. PubMed ID: 11363985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for third line therapy.
    Proj Inf Perspect; 2002 Mar; (34):8-9. PubMed ID: 12038303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and future issues in the treatment of HIV-1 infection.
    Matsushita S
    Int J Hematol; 2000 Jul; 72(1):20-7. PubMed ID: 10979204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
    Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for protease inhibitor failure.
    Proj Inf Perspect; 1997 Nov; (23):4-5. PubMed ID: 11365379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third line therapy options.
    Proj Inf Perspect; 1999 Apr; (27):9-11. PubMed ID: 11366743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing resistance costs of antiretroviral therapies via measures of future drug options.
    Jiang H; Deeks SG; Kuritzkes DR; Lallemant M; Katzenstein D; Albrecht M; DeGruttola V
    J Infect Dis; 2003 Oct; 188(7):1001-8. PubMed ID: 14513420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug watch.
    Whitson S
    Posit Aware; 2000; 11(1):18-9. PubMed ID: 11366337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Salvage therapy for HIV infection].
    Salzberger B
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():32-7. PubMed ID: 16385870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summaries from the Eleventh Annual Houston Conference on AIDS in America.
    Res Initiat Treat Action; 1999 Jul; 5(3):13-25. PubMed ID: 11366719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.